EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape

Hussein Zaitoon iD

Therapeutic Advances in Endocrinology and Metabolism · 2026-08 · 19

DOI: 10.1177/20420188261484779 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 24.08.2026. Verfasst von Hussein Zaitoon. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX, USA.

ORCID-Profile: Hussein Zaitoon

Zitieren

APA

Zaitoon, H. (2026). Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape. Therapeutic Advances in Endocrinology and Metabolism, 19. https://doi.org/10.1177/20420188261484779

Vancouver

Zaitoon H. Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape. Therapeutic Advances in Endocrinology and Metabolism. 2026;19. doi:10.1177/20420188261484779

BibTeX
@article{Zaitoon2026,
  author = {Zaitoon, Hussein},
  title = {Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape},
  journal = {Therapeutic Advances in Endocrinology and Metabolism},
  year = {2026},
  volume = {19},
  doi = {10.1177/20420188261484779}
}
Kostenlos starten →